Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome).
A 12-year-old Japanese girl with polyostotic fibrous dysplasia and endocrine concomitants, was treated with elcatonin, a synthetic eel calcitonin analogue, 10 MRC unit/twice a week given by intramuscular injection. Significant decreases in 24 hr urinary content of hydroxyproline and other amino acids from bone collagen were observed during the course of treatment over 5 months. This biochemical result suggests that the synthetic eel calcitonin analogue exhibits the therapeutic effect in patients with polyostotic fibrous dysplasia by inhibiting bone resorption.
D000469:Alkaline Phosphatase / Q000097:blood; D002116:Calcitonin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002118:Calcium / Q000097:blood; D002648:Child; D005260:Female; D005357:Fibrous Dysplasia of Bone / Q000652:urine*; D005359:Fibrous Dysplasia, Polyostotic / Q000652:urine*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D008239:Lysine / Q000652:urine; D010001:Osteitis Deformans / Q000378:metabolism; D010710:Phosphates / Q000097:blood; D011392:Proline / Q000652:urine
D010710:Phosphates; D002116:Calcitonin; D011392:Proline; D000469:Alkaline Phosphatase; D008239:Lysine; D006909:Hydroxyproline; D002118:Calcium; C012755:elcatonin